New cough drug candidate camlipixant tested in healthy volunteers

NCT ID NCT07684586

Terminated Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This phase 1 study tests camlipixant, a potential treatment for chronic cough, in 28 healthy adults. Researchers want to see how the body absorbs and processes different versions of the drug, and how food affects it. The main goal is to check safety and tolerability while measuring drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: camlipixant
What this could lead to: If successful, this study could help develop a more effective formulation of camlipixant for treating chronic cough.
What could go wrong: This is an early phase 1 study with only 28 healthy participants, so results may not predict effects in patients with cough. The drug may still fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COUGH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Cough Cough

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COUGH

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Nottingham, Nottinghamshire, NG11 6JS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.